Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Lianhua Qingwen Granted Market Access as Medicine in Ukraine: Yiling Pharmaceutical

SHIJIAZHUANG, China, June 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical disclosed in a statement on Monday that it had received the medicine registration document for Lianhua Qingwen Capsules from the Ministry of Health ofUkraine. As the leading product of Yiling Pharmaceutical, Lianhua Qingwen...

2021-06-29 16:41 3181

First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON

* Novel and one-time intravitreal injection of ND4 gene therapy for the treatment of LHON potentially restored vision * Phase I/II/III clinical trial expected to enroll patients with LHON due to ND4 mutation WUHAN, China and SAN DIEGO, June 28, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd...

2021-06-28 21:33 2284

ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury

DAEJEON, South Korea, June 28, 2021 /PRNewswire/ -- Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration withYonsei University of Seoul, South Korea. ...

2021-06-28 20:00 2063

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity Opaganib's unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect agai...

2021-06-28 19:00 13084

InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL

BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the trea...

2021-06-28 16:02 11068

Qbiotics concludes successful $85 million capital raise

* Capital raise nets $85 million from Existing Shareholders, Existing Institutional Investors, and cornerstone investor TDM Growth Partners. * Funding to enable human clinical development of the Company's anticancer drug candidate tigilanol tiglate and its wound healing drug candidate EBC-1013...

2021-06-28 09:36 3620

CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer

* Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) * In March 2021, GAVRETO was approved by the National Medical Products Administration (NMPA) ofChina for the treatment of patie...

2021-06-28 08:05 6789

Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery

SHANGHAI, June 26, 2021 /PRNewswire/ -- Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and ...

2021-06-26 23:00 4357

Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery

1 ... 340 341 342 343344